{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-243431","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.032376+00:00","generated_at":"2026-05-30T10:03:29.342111+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Revolution Medicines reports RMC-9805 clinical data: 30% ORR in 2L+ PDAC at 1,200 mg/day","bullets":["RMC-9805 monotherapy showed no Grade 4/5 TRAEs, no discontinuations; 3% dose reduction rate overall (179 patients).","For 2L+ PDAC patients (n=40) at 1,200 mg/day, ORR 30% (confirmed + pending), DCR 80%.","Most common any-grade TRAEs at 1,200 mg/day: nausea (27%), diarrhea (20%), vomiting (15%), rash (10%).","Median treatment duration 2.8 months across all doses; data cutoff September 2, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-243431","json":"https://secwatch.observer/filing/0001193125-24-243431.json","markdown":"https://secwatch.observer/filing/0001193125-24-243431.md","text":"https://secwatch.observer/filing/0001193125-24-243431.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312524243431/0001193125-24-243431-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312524243431/d890891d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:03:29.342111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}